Clinical Trial Update: A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose [Phase 1]

View source ↗

Summary

This Phase 1 pharmacokinetic study evaluated how moderate liver impairment affects the absorption, distribution, metabolism, and elimination of Sevabertinib aft…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Impairment
• Liver Disease

Drugs mentioned

• Sevabertinib (sevabertinib)

Snippet

Sponsor: Bayer | Conditions: Hepatic Insufficiency, Liver Diseases | Phase 1 | Status: COMPLETED